Recent news highlights include a full year sales increase reported in April 2026 and a capital raise through warrant exercises in January 2026. Analyst coverage includes maintained and initiated buy recommendations in late 2025.

• Vivos Therapeutics Inc reported a full year sales increase as of April 2026 [N2].
• The company announced closing of exercise of warrants for $4.64 million gross proceeds in January 2026 [N7].
• Ascendiant Capital maintained a buy recommendation for Vivos Therapeutics in December 2025 [N8].

The company’s pivot to a medical-provider focused model with acquisitions and management of sleep medical practices could increase patient access and treatment adoption of The Vivos Method. Initial operations at SCN demonstrate strong patient demand and high contribution margins per Sleep Optimization team. The broadening of clinical pathways and multidisciplinary provider engagement may expand the addressable market. The combination of proprietary FDA-cleared devices with adjunctive therapies offers a differentiated, non-surgical treatment option for OSA. Capital raises and warrant exercises provide funding to support growth initiatives. Continued expansion of the provider network and insurance participation could enhance revenue streams.

Vivos Therapeutics has a history of operating losses and negative cash flow, with significant accumulated deficits and liquidity constraints as of March 2026. The current ratio and cash ratio indicate limited short-term liquidity. The new business model is at an early stage, and operational scaling faces constraints including provider recruitment, insurance credentialing, and facility capacity. The company’s ability to increase revenues and achieve profitability is uncertain. Dependence on raising additional capital presents dilution and financing risks. Debt obligations related to acquisitions may strain cash flow. Changes in consumer preferences or reimbursement policies could adversely impact revenue. The company’s success depends on effective execution of its strategic pivot and market acceptance.

Vivos Therapeutics’ competitive strengths include its proprietary FDA-cleared oral appliances and comprehensive treatment protocols under The Vivos Method, which offer a non-surgical, limited-duration alternative to CPAP and surgical interventions for OSA. The company’s vertically integrated business model combining product sales with healthcare services through DSOs and MSOs provides operational control and potential for higher contribution margins. Its multidisciplinary approach involving dentists, medical doctors, and other healthcare professionals, supported by advanced diagnostic tools and billing services, differentiates it from competitors. The established network of trained providers and the Vivos Institute’s clinical education further support market penetration. The company’s strategic acquisitions and alliances with sleep centers enhance patient access and treatment acceptance, strengthening its market position.

• Profitability and Cash Flow Risk: The company has a history of net losses and negative cash flow, with no assurance of achieving profitability or positive cash flow from operations.
• Capital Raising and Dilution Risk: Vivos requires additional capital to fund operations and growth, which may result in dilution to existing shareholders or increased debt obligations.
• Operational Scaling Constraints: Growth is limited by physical space, provider recruitment and training, insurance credentialing, and onboarding of Sleep Optimization teams.
• Market Acceptance and Reimbursement Risk: Revenue depends on patient acceptance of The Vivos Method and availability of third-party insurance reimbursement, which may vary.
• Debt Service Risk: The company has significant debt related to acquisitions, including an $8.25 million secured promissory note, which requires cash flow allocation for servicing.

• Vivos Therapeutics, Inc. is a revenue stage medical technology and healthcare services company specializing in proprietary oral appliances and therapeutic treatments for maxillofacial and developmental abnormalities related to breathing and sleep disorders such as obstructive sleep apnea (OSA) and snoring in adults [S1].
• The company’s core treatment approach is called The Vivos Method, which combines oral appliances with specific therapeutic protocols and adjunctive treatments [S1].
• The Vivos Method is estimated to be indicated and potentially effective in approximately 80% of OSA cases where patients comply with clinical treatments [S1].
• The company’s patented C.A.R.E. oral appliances have been used in about 60,000 patients worldwide by over 2,000 trained dentists, with an additional 15,000 patients treated with other oral appliance lines [S1].
• Since 2024, Vivos has been evolving its business model from primarily training independent dentists to a medical-provider focused model involving acquisition and management of sleep medical practices and establishment of Dental and Medical Service Organizations (DSOs and MSOs) branded as Sleep and Airway Medicine Centers (SAMC) [S1].
• The new business model includes contractual alliances and acquisitions of sleep specialty medical providers and sleep testing centers, exemplified by the 2025 acquisition of The Sleep Center of Nevada (SCN) and a management agreement in Detroit, Michigan [S1].
• The company operates Sleep Optimization (SO) teams consisting of nurse practitioners, dentists, dental assistants, administrative staff, and treatment navigators to deliver OSA diagnostic and treatment services [S1].
• Initial operations at SCN have shown patient demand exceeding capacity, with constraints including physical space, provider recruitment, and insurance credentialing [S1].
• The company’s initial average case revenue and acceptance rate for Vivos treatment at SCN suggest each SO team could generate collections exceeding $500,000 per month with contribution margins above 50% [S1].
• Vivos offers multiple clinical pathways for providers: Guided Growth and Development (pediatric focus), Lifeline (mid-range mandibular advancement devices), and C.A.R.E. (flagship patented appliances for mild to severe OSA) [S1].
• As of April 2026, the Guided Growth and Development program is no longer offered to unaffiliated independent dentists but remains available to dentists employed or contracted with Vivos-supported DSOs [S1].
• The flagship C.A.R.E. program includes FDA 510(k) cleared DNA, mRNA, and mmRNA appliances for mild to severe OSA and snoring in adults, often combined with adjunctive therapies such as myofunctional therapy and chiropractic treatments [S1].
• The Vivos Method treatment course typically lasts 9 to 12 months and may eliminate the need for lifetime intervention, unlike CPAP or neuro-stimulation implants [S1].
• The company also provides diagnostic and support products and services including home sleep screenings (VivoScore), Treatment Navigator concierge services, Billing Intelligence Services, advanced training at the Vivos Institute, and MyoSync telemedicine-based myofunctional therapy [S1].
• The Vivos Institute is a clinical education center in Denver, Colorado, offering advanced training to a multidisciplinary group of healthcare professionals [S1].
• The company’s new medical-provider focused model aims to increase patient access, treatment acceptance, and revenue per case compared to the legacy dentist-focused model [S1].
• Vivos’s revenue sources include diagnostic and treatment revenue from SCN and MSO/DSO operations, appliance sales, and related services [S1].
• The company’s liquidity as of March 31, 2026, includes $2.11 million in cash and equivalents, current assets of $4.82 million, and current liabilities of $17.94 million, resulting in a current ratio of 0.27 and a cash ratio of 0.12 [S2].
• For the quarter ended March 31, 2026, Vivos reported a net loss of $7.68 million and basic and diluted EPS of -$0.52 per share [S2].
• The company has a history of operating losses and negative cash flow, with net losses of $21.2 million in 2025 and $11.1 million in 2024, and an accumulated deficit of approximately $125.4 million as of December 31, 2025 [S1].
• Vivos has raised capital through private placements, warrant exercises, and ATM offerings, including a $4.64 million gross proceeds from warrant exercises in January 2026 [N7][S1].
• The company faces risks related to its ability to increase revenues, achieve profitability, raise additional capital, and manage debt obligations, including an $8.25 million secured promissory note related to the SCN acquisition [S1][S2].
• Recent news includes a report of full year sales increase for Vivos Therapeutics, Inc. as of April 2026 [N2].
• Vivos announced closing of exercise of warrants for $4.64 million gross proceeds in January 2026 [N7].
• Analyst coverage includes buy recommendations maintained by Ascendiant Capital and initiated by HC Wainwright & Co. in late 2025 [N8].